Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method

Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

(2011) Carlos Gómez-Martín et al.   Clinical & Translational Oncology

Visualization of FISH Probes by Dual-Color Chromogenic In Situ Hybridization

(2010) Kirsten Hoff et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma

(2010) Bettina G. Papouchado et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

(2010) H. J. Ross et al.   CLINICAL CANCER RESEARCH

Determination ofHER2amplification in primary breast cancer using dual-colour chromogenicin situhybridization is comparable to fluorescencein situhybridization: a European multicentre study involving 168 specimens

(2010) Tomás García-Caballero et al.   HISTOPATHOLOGY

A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations

(2010) Bárbara Angulo et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

The HER2 testing conundrum

(2010) Malorye Allison   NATURE BIOTECHNOLOGY

Chromogenic In Situ Hybridization

(2009) J.M.S. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

(2009) M. Lae et al.   ANNALS OF ONCOLOGY

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

(2009) J D Barros-Silva et al.   BRITISH JOURNAL OF CANCER

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

(2009) Kathryn A. Phillips et al.   CANCER

Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays

(2009) Glenn D. Francis et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

The Correlation Between Dual-color Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization in Assessing HER2 Gene Amplification in Breast Cancer

(2009) Marianne Pedersen et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Evaluation of automated silver-enhancedin situhybridization (SISH) for detection ofHER2gene amplification in breast carcinoma excision and core biopsy specimens

(2009) S Shousha et al.   HISTOPATHOLOGY

Chromogenicin situhybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenicin situhybridization with immunohistochemistry and fluorescencein situhybridization

(2009) Doris Mayr et al.   HISTOPATHOLOGY

HER-2 amplification is highly homogenous in gastric cancer

(2009) Andreas H. Marx et al.   HUMAN PATHOLOGY

HER-2 amplification is highly homogenous in gastric cancer

(2009) Michael Bilous et al.   HUMAN PATHOLOGY

Fluorescent In Situ Hybridization for Human Epidermal Growth Factor Receptor 2 Assessment in Breast Cancer: Is It Applicable As a Primary Test?

(2009) Vincenzo Arena et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

(2009) Sumithra J. Mandrekar et al.   JOURNAL OF CLINICAL ONCOLOGY

Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: A comparison with fluorescence in situ hybridization study

(2009) Seol Bong Yoo et al.   LUNG CANCER

Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas

(2009) Timo Gaiser et al.   MODERN PATHOLOGY

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients

(2008) Zhiyong Liang et al.   BMC CANCER

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)

(2008) Hiroaki Nitta et al.   Diagnostic Pathology

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists

(2008) Antonino Carbone et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases

(2008) Mamatha Chivukula et al.   MODERN PATHOLOGY

Monoplex LightCycler Polymerase Chain Reaction Quantitation of the HER2 Gene for Quality Assurance of HER2/neu Testing by Immunohistochemistry and Fluorescence In Situ Hybridization

(2008) Lester J. Layfield et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY